NCI-H3122/NCI-H3122/NCI-H3122/

NCI-H3122/NCI-H3122细胞系/NCI-H3122细胞株/NCI-H3122人非小细胞肺癌细胞

Cell line name NCI-H3122

Synonyms H3122; H-3122; NCIH3122

Accession CVCL_5160

Resource Identification Initiative To cite this cell line use: NCI-H3122 (RRID:CVCL_5160)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Population: Caucasian.

Doubling time: 48.5 hours (PubMed=29681454).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.

Sequence variations

Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK; Note=E13A20 v1 fusion (PubMed=18594010; DOI=10.1101/2022.06.08.495301; DepMap=ACH-000337).

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0

Native American 0

East Asian, North 1.36

East Asian, South 0

South Asian 1.48

European, North 65.9

European, South 31.26

Disease Lung adenocarcinoma (NCIt: C3512)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_4Y37 (NCI-H3122-CHR-A1) CVCL_AY53 (NCI-H3122-CR1)

Sex of cell Male

Age at sampling 54Y

Category Cancer cell line

STR profile Source(s): CLS=300484; Cosmic-CLP=1240190; PubMed=20679594

 

Markers:

Amelogenin X

CSF1PO 11,12

D5S818 11,12

D7S820 8,12

D8S1179 13,15

D13S317 10,12

D16S539 11,12

D18S51 13,16

FGA 18,21

Penta D 10,13

Penta E 12

TH01 7,9.3

TPOX 10

vWA 16

 

Run an STR similarity search on this cell line

Publications

PubMed=11030152; DOI=10.1038/sj.onc.1203815

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Oncogene 19:4632-4639(2000)

 

PubMed=12759538; DOI=10.1159/000070299

Fujishita T., Loda M., Turner R.E., Gentler M., Kashii T., Breathnach O.S., Johnson B.E.

Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of paclitaxel.

Oncology 64:399-406(2003)

 

PubMed=18594010; DOI=10.1158/1078-0432.CCR-08-0168; PMCID=PMC3025451

Koivunen J.P., Mermel C.H., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J., Richards W.G., Sugarbaker D.J., Ducko C.T., Lindeman N.I., Marcoux J.P. 2nd, Engelman J.A., Gray N.S., Lee C., Meyerson M.L., Janne P.A.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Clin. Cancer Res. 14:4275-4283(2008)

 

PubMed=20679594; DOI=10.1093/jnci/djq279; PMCID=PMC2935474

Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.

Lung cancer cell lines as tools for biomedical discovery and research.

J. Natl. Cancer Inst. 102:1310-1321(2010)

 

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112; PMCID=PMC3567922

Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Cancer Discov. 2:798-811(2012)

 

PubMed=23344087; DOI=10.1097/JTO.0b013e318283dcc0

Kim S., Kim T.M., Kim D.-W., Go H., Keam B., Lee S.-H., Ku J.-L., Chung D.H., Heo D.S.

Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.

J. Thorac. Oncol. 8:415-422(2013)

 

PubMed=24675041; DOI=10.1158/2159-8290.CD-13-0846; PMCID=PMC4068971

Friboulet L., Li N.-X., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., Michellys P.-Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C., Li J., Kasibhatla S., Sun F., Sun X.-Y., Hua S., McNamara P., Mahmood S., Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T., Engelman J.A.

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Cancer Discov. 4:662-673(2014)

 

PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003

Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C., Daub H.

Comparative proteome analysis across non-small cell lung cancer cell lines.

J. Proteomics 130:1-10(2016)

 

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miro T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

 

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051; PMCID=PMC6343826

Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

Differential effector engagement by oncogenic KRAS.

Cell Rep. 22:1889-1902(2018)